

Biomarkers predict time to ovarian cancer recurrence

15 August 2013

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated in ovarian cancer prognosis. However, the genetic testing required is not practical or affordable in a clinical setting.

In this issue of the *Journal of Clinical Investigation*, Roel Verchaak and colleagues at the MD Anderson Cancer Center identify protein biomarkers that are predictive for time of ovarian <u>cancer recurrence</u> and develop a PRotein-driven index of OVARian cancer (PROVAR).

Using PROVAR, the authors were able to discriminate between patients with high and low risk of cancer recurrence, as well as short-term and long-term survival prognosis. In combination with genetic diagnosis, analysis of <u>protein</u> <u>biomarkers</u> may be useful in predicting outcome and determining a treatment plan for ovarian cancer patients.

More information: Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers, *J Clin Invest*. DOI: 10.1172/JCI68509

Provided by Journal of Clinical Investigation

APA citation: Biomarkers predict time to ovarian cancer recurrence (2013, August 15) retrieved 4 May 2021 from <u>https://medicalxpress.com/news/2013-08-biomarkers-ovarian-cancer-recurrence.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.